Photodynamic Diagnosis and Narrow-Band Imaging in the Management of Bladder Cancer: A Review

Kutwin, Piotr; Konecki, Tomasz; Cichocki, Marcin; Falkowski, Piotr; Jabłonowski, Zbigniew

doi:10.1089/pho.2016.4217

Cited by 26 publications

(22 citation statements)

References 44 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…CIS tumors were excluded from our research for 2 reasons: 1) it was not appropriate to use MMC as intravesical adjuvant chemotherapy compared to BCG in our patients because CIS tumors were associated with significantly higher progression and recurrence rate [18 -20]. It is also clearly advised by the NCCN guidelines that BCG should be used alone as CIS post-TURBT intravesical treatment, according to several research reports [15,21,22]; and 2) the rate of CIS diagnosis was only approximately 70 % through white-light endoscopy due to its variable shape [23]. In addition, it can present as a velvet-like, reddish area indistinguishable from inflammation, or may even be invisible.…”

Section: Discussionmentioning

confidence: 99%

“…Although the photodynamic diagnosis has recently been proven to demonstrate a superior diagnosis rate, it was not prevalent when we examined our patients because of the following reasons: 1) apparently, patients with intravesical chemotherapy within 6 months exhibited markedly more false-positive biopsy rate, possibly resulting in more unnecessary treatment to our patient [7]; 2) a meta-analysis revealed that the sensitivity of the photodynamic diagnosis was 94 % for the detection of all bladder tumors compared with 87 % for white-light cystoscopy, and whether it is imperative to use the photodynamic diagnosis for each patient rather than Tis (we have excluded this group) remains controversial [23]; and 3) the high cost of equipment was not accepted by each patient and clinic, particularly when it does not offer the progression benefit but a recurrence benefit [23].…”

Section: Discussionmentioning

confidence: 99%

See 1 more Smart Citation

Comparison of Different Treatment Schedules of Mitomycin C Intravesical Instillation in High-Risk Superficial Bladder Cancer Patients

et al. 2018

View full text Add to dashboard Cite

Objective This study was performed to compare the efficacy of intravesical mitomycin C (MMC) instillation for the prophylaxis of Ta or T1 high-risk nonmuscle invasive bladder cancer (NMIBC) using different schedules. Materials and methods This retrospective cohort study was conducted on 152 patients treated with intravesical MMC from April 2009 to September 2016. The mean follow-up time was 32.67 months. All patients underwent a complete transurethral resection of bladder tumor (TURBT) and postoperative instillation of MMC within 24 h. The patients were divided into 4 treatment groups: Group 1 was followed-up without any maintenance MMC dose treatment; Group 2 received an MMC instillation once per week for the first 8 weeks; Group 3 received an MMC instillation once per week for the first 8 weeks, and once per month for the following 6 months; and Group 4 received an MMC instillation once per week for the first 8 weeks, and once per month for the following 12 months. Results The overall recurrence rate was 27.6 %. Group 1 had a significantly high (p < 0.05) recurrence rate of 50 %, while there was no difference in the recurrence rate between the last 3 schedules (Group 2:15 %; Group 3: 24.1 %; group 4: 27.2 %). Moreover, the recurrence rates of Ta or T1 tumors, and low-grade or high-grade tumors were not statistically different among these patient groups. Conclusion Our comparison of the different schedules of intravesical MMC instillation revealed a significantly higher recurrence rate with one MMC instillation post-TURBT than in patients with a maintenance dose of 8 weeks, 6 months, and 12 months. The time of the MMC maintenance schedule exhibited no significant differences between 8 weeks and 12 months. Thus, we conclude that for T1 or Ta high-risk NMIBC, MMC instillation can be performed once after TURBT, followed by a maintenance treatment once per week for 8 weeks.

show abstract

Section: Discussionmentioning

confidence: 99%

Section: Discussionmentioning

confidence: 99%

Comparison of Different Treatment Schedules of Mitomycin C Intravesical Instillation in High-Risk Superficial Bladder Cancer Patients

et al. 2018

View full text Add to dashboard Cite

show abstract

“…Hatta görülmeyen şüpheli alanların tespit edilmesini sağlayabilir. NBI teknolojisi özellikle pelvikalisyel sistem içindeki şüpheli alanların biyopsileri veya lazer ablasyonu gibi tümör çalışmaları için kullanıldığında daha faydalıdır (9,(11)(12)(13)(14), (Resim 2).…”

Section: Fleksibl Urs'lerde Teknolojik Gelişimunclassified

URS Konusunda Teknolojik Gelişmeler

Bedir¹

2017

Endouroloji

View full text Add to dashboard Cite

“…It is based on photosensitizers and laser light with a specific wavelength, causing the production of reactive oxygen species (ROS) and inducing tumor cell apoptosis/necrosis (16). PDT has been clinically used for various cancers, including cervical (17), lung(18), bladder (19), skin (20) and head and neck cancers (5,21).…”

Section: Introductionmentioning

confidence: 99%

MPPa-PDT suppresses breast tumor migration/invasion by inhibiting AKT-NF-κB-dependent MMP-9 expression via ROS

Huang

Lin

Chen

et al. 2019

Preprint

View full text Add to dashboard Cite

Background: Breast cancer is one of the most commonly diagnosed cancers in women, with high morbidity and mortality. Tumor metastasis is implicated in most breast cancer deaths; thus, inhibiting metastasis may provide a therapeutic direction for breast cancer. In the present study, pyropheophorbide-α methyl ester-mediated photodynamic therapy (MPPa-PDT) was used to inhibit metastasis in MCF-7 breast cancer cells. Methods: Uptake of MPPa was detected by fluorescence microscopy. Cell viability was evaluated by the Cell Counting Kit-8 (CCK-8). ROS generation was detected by 2',7'-dichlorodihydrofluorescein diacetate (DCFH-DA). The migration of cells was assessed by wound healing assay, and invasion ability was assessed by Matrigel invasion assay. Levels of MMP2 and MMP9 were measured by PCR. Akt, phospho-Akt (Ser473), phospho-NF-κB p65 (Ser536) and NF-κB p65 were measured by western blotting. The F-actin cytoskeleton was observed by immunofluorescence. Lung tissue was visualized by hematoxylin and eosin staining. Results: Following MPPa-PDT, migration and invasion were decreased in the MCF-7 cells. MPPa-PDT downregulated the expression of MMP2 and MMP9, which are responsible for the initiation of metastasis. MPPa-PDT reduced the phosphorylation of Akt and NF-κB. MPPa-PDT also reduced and destroyed the F-actin cytoskeleton in MCF-7 cells. These effects were blocked by the reactive oxygen species scavenger NAC or the Akt activator SC79, while the PI3K inhibitor LY294002 or the Akt inhibitor triciribine enhanced these effects. Moreover, MPPa-PDT inhibited tumor metastasis and destroyed F-actin in vivo. Conclusion: Taken together, these results demonstrate that MPPa-PDT inhibits the metastasis of MCF-7 cells both in vitro and in vivo and may be involved in the Akt/NF-κB-dependent MMP-9 signaling pathway. Thus, MPPa-PDT may be a promising treatment to inhibit metastasis. Key words: photodynamic therapy, reactive oxygen species, breast tumor, migration, invasion

show abstract

Photodynamic Diagnosis and Narrow-Band Imaging in the Management of Bladder Cancer: A Review

Abstract: Although the high cost of the equipment may limit its introduction to everyday use, it is a cost-effective method of bladder cancer management for long-term follow-up.

Cited by 26 publications

References 44 publications

Comparison of Different Treatment Schedules of Mitomycin C Intravesical Instillation in High-Risk Superficial Bladder Cancer Patients

Comparison of Different Treatment Schedules of Mitomycin C Intravesical Instillation in High-Risk Superficial Bladder Cancer Patients

URS Konusunda Teknolojik Gelişmeler

MPPa-PDT suppresses breast tumor migration/invasion by inhibiting AKT-NF-κB-dependent MMP-9 expression via ROS

Contact Info

Product

Resources

About